About this visual
An archived visual of projected obesity-medication milestones across oral semaglutide, higher-dose Wegovy, orforglipron, CagriSema, retatrutide, survodutide, and MariTide.
Sources & further reading
Further reading: Current OMV therapy pipeline ↗
Historical forecast. Dates and expected results in the image are not current clinical or regulatory guidance. The exact original post date was not independently verified.




The future of obesity medicine looks incredibly bright.
Over the past few years, obesity treatment has evolved faster than almost any other area of medicine. What’s coming next may be even more transformative.
I put together an infographic to summarize several upcoming obesity medications currently in late-stage development, along with their mechanisms, estimated timelines, and approximate weight loss efficacy based on the most recent clinical trial data.
Medications highlighted in the graphic include:
• Oral Wegovy - GLP-1 receptor agonist - ~13 to 17% estimated weight loss
• Wegovy 7.2 mg - Higher-dose injectable GLP-1 - ~20 to 21% estimated weight loss
• Orforglipron - Oral non-peptide GLP-1 agonist - ~11 to 15% estimated weight loss
• CagriSema - Amylin analog + GLP-1 agonist - ~20 to 23% estimated weight loss
• Retatrutide - Triple agonist (GIP, GLP-1, glucagon) - up to ~28 to 29% estimated weight loss
• Survodutide - Dual agonist (GLP-1, glucagon) - ~15 to 19% estimated weight loss
• MariTide - GIP antagonist + GLP-1 antibody-drug conjugate - ~18 to 20% estimated weight loss
A few important notes for context:
• The percentages shown are trial-based estimates and vary by dose, duration, and analysis method
• Timelines reflect best estimates, not guarantees
• Real-world outcomes will depend on access, tolerability, and individualized care
That said, the direction is clear. We are seeing more options, new mechanisms, and levels of efficacy that were unimaginable just a few years ago, including oral therapies and medications approaching weight loss previously seen only with surgery.
It is an exciting time for patients and providers alike, and I am hopeful these advances will continue to improve access, affordability, and long-term outcomes.
#ObesityMedicine #MetabolicHealth #GLP1 #ClinicalTrials #HealthcareInnovation #Semaglutide #Orforglipron #CagriSema #Retatrutide #Wegovy